Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Atomoxetine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.
- 15 Oct 2006 New trial record.